Please login to the form below
Ready to Engage
Recent events have brought to a head Europe's discord over the practice of parallel trade
Recent events have brought to a head Europe's discord over the practice of parallel trade. Opinions on its value are diametrically opposed, with some condemning it as a danger to patients and others asserting that it generates savings for healthcare systems. A key point of current debate, however, is whether it lets criminal counterfeiters into the supply chain
The argument against parallel trade
Some feel that parallel trade weakens security, enabling drug counterfeiters to enter and pollute legitimate supply chains
Read more
The argument for parallel trade
others believe that today's well-regulated parallel trade creates much-needed savings for europe's healthcare systems
Read more
Pharma speaks out
glaxosmithkline has recently experienced victory over parallel traders in greek courts - Alice Hunt talks about the outcomes
Read more
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- AZ’s COVID-19 vaccine trial to continue after Brazilian volunteer death
- FDA sets November date for expert panel review of Biogen’s aducanumab
- Pfizer CEO pushes back COVID-19 vaccine submission to November
- Novartis scores CHMP backing for cholesterol drug Leqvio
- GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year
- Moderna’s chief exec expects to have COVID-19 vaccine data in November
- Eliminating pharmaceutical rebates, is this déjà vu?
- Bayer pays an initial $2bn for gene therapy firm AskBio
- Both AZ and J&J set to resume US COVID-19 vaccine trials
- AZ’s COVID-19 vaccine shows promise in younger and older adults
- Bayer's drop of the future
- Patients are ready to embrace decentralised clinical trials, are you?
PMHub
90TEN
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...
Latest intelligence
- Eliminating pharmaceutical rebates, is this déjà vu?
- By Andrew Parece and Matthew Majewski...
- Patients are ready to embrace decentralised clinical trials, are you?
- Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
- Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
- The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
Quick links
Infographics
